Castlefield Investment Partners LLP purchased a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 41,797 shares of the company’s stock, valued at approximately $5,371,000. Merck KGaA comprises approximately 3.6% of Castlefield Investment Partners LLP’s investment portfolio, making the stock its 11th largest position.
A number of other institutional investors have also made changes to their positions in MKGAF. Frazier Financial Advisors LLC bought a new stake in Merck KGaA in the second quarter valued at about $25,000. Rakuten Securities Inc. bought a new position in Merck KGaA during the second quarter worth about $27,000. Solstein Capital LLC bought a new position in Merck KGaA during the second quarter worth about $33,000. Burk Holdings LLC acquired a new position in shares of Merck KGaA during the 2nd quarter worth about $39,000. Finally, Bard Associates Inc. acquired a new position in shares of Merck KGaA during the 2nd quarter worth about $60,000. 0.10% of the stock is owned by institutional investors and hedge funds.
Merck KGaA Stock Performance
Shares of MKGAF stock opened at $163.21 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. The stock has a market cap of $21.09 billion, a PE ratio of 24.92 and a beta of 0.96. The stock has a 50-day moving average of $162.62 and a 200-day moving average of $148.44. Merck KGaA has a one year low of $116.68 and a one year high of $175.56.
Merck KGaA Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Articles
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
